- Comparison table: Some lipid-lowering drugs. [Journal Article]Med Lett Drugs Ther 2019; 61(1565):e24-e30ML
- Drugs and Lactation Database (LactMed): Colestipol [BOOK]National Library of Medicine (US): Bethesda (MD)BOOK
- Colestipol is a nonabsorbable resin. Because it does not enter the mother's bloodstream, it will not reach the infant via breastmilk. It is acceptable for use during lactation.
Colestipol is a nonabsorbable resin. Because it does not enter the mother's bloodstream, it will not reach the infant via breastmilk. It is acceptable for use during lactation.
- Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. [Journal Article]Stroke 2018; 49(5):1148-1154S
- CONCLUSIONS: Higher HDL values and the use of lipid-lowering agents are significantly inversely associated with ruptured intracranial aneurysms.
- Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide. [Clinical Trial]Expert Rev Clin Pharmacol 2017; 10(12):1403-1407ER
- CONCLUSIONS: The administration of colestipol HCl for 15 days was sufficient to reduce plasma teriflunomide concentrations by greater than 96%. Although colestipol HCl did not completely eliminate teriflunomide with the same effectiveness as cholestyramine, it may offer an alternative method for accelerated elimination of teriflunomide with potentially improved tolerability and more favorable dosing and administration options.
- Statins for children with familial hypercholesterolemia. [Review]Cochrane Database Syst Rev 2017; 7:CD006401CD
- CONCLUSIONS: Statin treatment is an effective lipid-lowering therapy in children with familial hypercholesterolemia. No significant safety issues were identified. Statin treatment seems to be safe in the short term, but long-term safety remains unknown. Children treated with statins should be carefully monitored and followed up by their pediatricians and their care transferred to an adult lipidologist once they reach 18 years of age. Large long-term randomized controlled trials are needed to establish the long-term safety issues of statins.
- Treatment of Severe Hypercholesterolemia in a Woman With Advanced Primary Sclerosing Cholangitis. [Case Reports]JAMA Cardiol 2017; 2(5):575-576JC
- 75SeHCAT scan in bile acid malabsorption in chronic diarrhoea. [Review]Rev Esp Med Nucl Imagen Mol 2017 Jan - Feb; 36(1):37-47RE
- Chronic diarrhoea is a common entity in daily clinical practice and it leads to a loss in these patients quality of life. It may be the main symptom of multiple ethiologies including bile acid malabsorption (BAM) which has a comparable prevalence to celiac disease. The BAM results from imbalances in the homeostasis of bile acids in the enterohepatic circulation. It can be a consequence of ileal d…
Chronic diarrhoea is a common entity in daily clinical practice and it leads to a loss in these patients quality of life. It may be the main symptom of multiple ethiologies including bile acid malabsorption (BAM) which has a comparable prevalence to celiac disease. The BAM results from imbalances in the homeostasis of bile acids in the enterohepatic circulation. It can be a consequence of ileal disease or ileal dysfunction (BAM type i), it can be considered idiopathic or primary (BAM type ii) or associated with other gastrointestinal entities (BAM type iii). Among the different diagnostic methods available, 75SeHCAT study is the primary current method due to its sensitivity, specificity, safety and low cost. The main disadvantage is that it's not available in all countries, so other diagnostic methods have appeared, such as serum measurement of FGF19 and C4, however they are significantly more complex and costly. The first-line treatment of bile acid diarrhoea is bile acid sequestrant, such as cholestyramine, which can be difficult to administer due to its poor tolerability and gastrointestinal side effects. These are less prominent with newer agents such as colesevelam. In summary, the BAM is a common entity underdiagnosed and undertreated, so it is essential to establish a diagnosis algorithm of chronic diarrhoea in which the 75SeHCAT study would be first or second line in the differential diagnosis of these patients.
- Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. [Journal Article]J Clin Lipidol 2016 Sep-Oct; 10(5):1091-7JC
- CONCLUSIONS: Long-term intensive lipid therapy significantly reduced total and cardiovascular mortality in Familial Atherosclerosis Treatment Study-Observational Study. These results support the importance of lifetime risk management to improve long-term outcome.
New Search Next
- Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [BOOK]Agency for Healthcare Research and Quality (US): Rockville (MD)BOOK
- CONCLUSIONS: We found no direct evidence of the effect of screening on intermediate or health outcomes. The evidence describing the diagnostic yield of screening for FH in children is minimal. There is good evidence of the effectiveness of statins in reducing LDL-C and TC concentrations in studies up to 2 years long and limited evidence of a statin effect on measures of atherosclerosis. Statins were generally well-tolerated in the short term, although reversible elevations of liver enzymes and/or creatine kinase concentrations were noted in some studies and a decrease in dehydroepiandrosterone sulfate was noted in one study. Bile-acid binding resins were commonly associated with adverse gastrointestinal symptoms and poor palatability. Long-term harms are unknown. Randomized trials of screening for FH in U.S. youth are needed, as are longer-term treatment trials evaluating the benefits and harms of medications in children and adolescents with FH.